The Publication Spotlighting UAE's Oncology Fortitude

In a timely contribution to global health discourse, a new article published in Frontiers in Oncology titled "Cancer Care Cannot Wait: Oncology System Resilience in the UAE During Regional Conflict in the Gulf" underscores the United Arab Emirates' (UAE) remarkable ability to sustain advanced cancer treatment amid escalating regional tensions. Authored by leading oncologists including Humaid O. Al-Shamsi from Burjeel Medical City in Abu Dhabi, the paper draws from real-time clinical observations during the crisis that intensified on February 28, 2026, with missile and drone attacks targeting key infrastructure across the Gulf. Despite these threats, UAE's oncology services experienced zero interruptions in chemotherapy, radiotherapy, or supportive therapies, a testament to proactive national strategies.

The study highlights how the UAE, facing a high burden of young-onset cancers—25.4% diagnosed under age 40 and 49% under 49 according to the 2021 UAE Cancer Registry—prioritized continuity of care. This resilience not only protected local patients but also positioned the UAE as a regional hub, absorbing cancer patients displaced from conflict zones abroad without delays.

UAE's Advanced Oncology Infrastructure Pre-Conflict

Over the past two decades, the UAE has invested heavily in world-class oncology infrastructure. Coordinated by the Ministry of Health and Prevention (MOHAP), Abu Dhabi Department of Health (DoH), and Dubai Health Authority (DHA), the nation boasts tertiary centers equipped with state-of-the-art linear accelerators for precision radiotherapy, PET-CT scanners for diagnostics, and multidisciplinary tumor boards. Burjeel Medical City in Abu Dhabi stands out as a flagship facility, offering comprehensive services from proton therapy consultations to CAR-T cell therapies, recently launching a Neuro-Oncology Centre to address brain tumors.

National digital health platforms like Malaffi enable seamless sharing of portable electronic medical records (EMRs), ensuring patients can access care across emirates or even internationally. The Emirates Drug Establishment (EDE) oversees pharmaceutical stockpiling, maintaining reserves of temperature-sensitive oncology drugs like monoclonal antibodies and chemotherapeutics, critical given global supply vulnerabilities.

Context of the 2026 Gulf Regional Conflict

The conflict escalated dramatically on February 28, 2026, with coordinated missile and drone strikes from Iran-backed groups targeting energy facilities, airports, and ports in the Gulf, including UAE airspace. While UAE air defenses intercepted most threats, disruptions rippled through regional logistics. Pharma supply chains faced severe challenges: key air routes via Iraq and sea lanes through the Strait of Hormuz were rerouted, delaying refrigerated shipments of biologics and cytotoxics essential for cancer treatment. Reports indicated up to 48-hour delays for some oncology drugs into Dubai and Abu Dhabi airports, heightening risks for time-critical therapies.

Globally, conflicts like those in Iraq (ISIL era) and Ukraine have led to 50-70% drops in radiotherapy sessions and chemotherapy stockouts lasting weeks. The UAE study contrasts this, attributing success to preemptive planning aligned with the Global Summit on War and Cancer 2024 frameworks.

Key Challenges Faced by UAE Oncology During the Crisis

Primary threats included potential infrastructure damage to hospitals and logistics hubs, workforce safety (UAE oncology relies on 80-90% expatriate professionals), and supply chain bottlenecks for imported drugs (95% of advanced oncology meds). Patient anxiety led to initial no-shows, but targeted communication reversed this. Returning expatriate patients from disrupted overseas treatments strained capacity, yet systems absorbed them seamlessly.

Photo by Shengnan Gao on Unsplash

• Logistics: Rerouting via Europe added costs and risks to cold-chain integrity for drugs like trastuzumab and rituximab.
• Workforce: Travel bans and family concerns tested retention, but contractual commitments and on-site housing prevailed.
• Patient Access: Road closures and flight cancellations, mitigated by tele-oncology and shuttle services.

Proven Resilience Strategies in Action

The paper delineates five pillars of UAE's success: robust governance, digital infrastructure, supply chain fortification, human capital, and public trust. MOHAP activated national emergency protocols, integrating civil defense with healthcare ops centers. EDE's strategic reserves ensured no drug shortages, even as Gulf-wide delays hit competitors.

Digital tools shone: EMR portability allowed instant handovers, while teleconsults maintained tumor board meetings. Psychological support via hotlines and apps addressed fear, boosting attendance to pre-conflict levels within days. At Burjeel Medical City, multidisciplinary teams upheld full schedules, treating over 200 patients daily without pause.

Burjeel Medical City's Pivotal Role

As a key author affiliation, Burjeel Medical City exemplified resilience. This 650-bed facility, with dedicated oncology wings, maintained 100% operational uptime. It rapidly onboarded 150+ displaced patients from Lebanon and Iraq, leveraging proton beam planning and immunotherapy suites. Recent expansions, like the Neuro-Oncology Centre launched March 30, 2026, enhance specialized care amid ongoing tensions. Dr. Al-Shamsi, CEO of Burjeel Cancer Institute, notes: "Our systems were battle-tested, proving that preparation trumps reaction."

Read the full open-access study here for detailed case examples.

Patient Outcomes and Public Confidence

Critically, patient metrics remained stable: no excess treatment delays, adherence rates held at 95%, and emergency oncology visits showed no surge from complications. Public trust was pivotal—patients prioritized appointments despite alerts, reflecting faith in UAE's interception capabilities (99% success rate). Post-crisis surveys at centers like Burjeel reported 92% satisfaction with continuity.

This contrasts global norms where conflict halves survival rates; UAE's model offers a blueprint.

Lessons Learned and Global Implications

The study proposes a resilience framework: 1) Governance integration, 2) Digital interoperability, 3) Stockpile mandates, 4) Workforce incentives, 5) Patient engagement. For Gulf neighbors, it urges similar investments. Broader MENA implications include positioning UAE as a safe haven for cancer care tourism, potentially boosting medical GDP contribution (currently 5%).

Future research needs: Prospective audits of delay impacts and long-term survival data. As conflicts persist, UAE's experience informs WHO guidelines on oncology in fragile states.Reuters on supply disruptions.

Photo by Kate Trysh on Unsplash

Future Outlook for UAE Oncology Amid Geopolitical Risks

Looking ahead, UAE aims to cut cancer mortality 18% by 2025 (ongoing KPI), with expansions like Burjeel's radiation network across GCC. AI-driven predictive logistics and domestic drug manufacturing (e.g., biosimilars) will harden supply chains. Academic collaborations, such as with RAK Medical University, foster research on conflict-resilient protocols.

Stakeholders emphasize: "Prepared systems can sustain care even in instability," urging global adoption.

In summary, this publication not only documents UAE's triumph but inspires resilient healthcare worldwide, proving cancer care indeed cannot—and should not—wait.